section name header

Pronunciation

tran-ex-AM-ikAS -id

Classifications

Therapeutic Classification: hemostatic agents

Pharmacologic Classification: antifibrinolytics, plasminogen inactivators

Indications

REMS


Action

  • Inhibits activation of plasminogen, thereby preventing the conversion of plasminogen to plasmin.
Therapeutic effects:
  • Decreased bleeding following dental surgery in hemophiliacs.
  • Reduced need for replacement therapy.
  • Reduced menstrual blood loss.

Pharmacokinetics

Absorption: 100% bioavailable with IV administration; 45% bioavailability after oral administration.

Distribution: Penetrates readily into joint fluid and synovial membranes.

Metabolism/Excretion: 95% excreted unchanged in urine.

Half-Life: 2 hr (IV) ( in renal impairment); 11 hr (PO).

Time/Action Profile

(blood levels)

ROUTEONSETPEAKDURATION
IVunknownunknown7–8 hr
POunknown2.5 hrunknown



Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

CNS: SEIZURES, headache, dizziness

EENT: visual abnormalities

CV: hypotension, thromboembolism, thrombosis

GI: diarrhea, nausea, vomiting

MS: pain

Misc:

PO

ANAPHYLAXIS

Interactions

Drug-drug:

Route/Dosage

Renal Impairment

Renal Impairment

Availability

(Generic available)

Assessment

Implementation

IV Administration:

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Cyklokapron, Lysteda

Pot. Nursing Diagnoses

Code

NDC Code